奈达铂联合多西他赛治疗晚期非小细胞肺癌的近期疗效及安全性分析

Short-term Efficacy and Safety of Nedaplatin Combined with Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer

目的:观察奈达铂联合多西他赛治疗晚期非小细胞肺癌(NSCLC)的近期疗效及安全性。方法:50例符合入组条件的晚期NSCLC患者随机分为2组,均给予多西他赛75mg·m-2,静脉滴注2h,第1天。治疗组30例,加予奈达铂100mg·m-2,静脉滴注,第1天;对照组20例,加予卡铂400～500mg,静脉滴注,第1天。21d为1个周期,2个周期后评价疗效。结果:治疗组总有效率为53.33%,对照组总有效率为50.00%,差异无统计学意义(P>0.05);2组毒副反应比较差异无统计学意义(P>0.05)。结论:奈达铂联合多西他赛治疗晚期NSCLC近期疗效和安全性与卡铂联合多西他赛相当,但远期疗效仍需进一步观察。

OBJECTIVE：To observe the short-term efficacy and safety of nedaplatin （NDP） combined with docetaxel （TAX） in the treatment of advanced non-small cell lung cancer （NSCLC）.METHODS：50 cases of advanced NSCLC were randomized into therapy group and control group.Both group received intravenous drip infusion of TAX 75 mg·m-2 in 2 hours,first day.Therapy group were additionally given intravenous drip infusion of NDP 100 mg·m-2 （n=30） and control group carboplati 400～500 mg.One therapy course contained 21 days and clinical efficacy was evaluated after 2-weeks regimen.RESULTS：The total effective rates were 53.33% for therapy group and 50.00% for control group,there was no statistically significance （P0.05）;The difference of toxic side reaction between 2 groups had no statistically significance （P0.05）.CONCLUSION：Nedaplatin combined with docetaxel is effective and safe for advanced NSCLC with high short-term efficacy and mild toxic side reaction in digestive tract and kidney.but the long-term efficacy of it require further study.